CoChat

A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs)

Open access
Miller, Michael L., Shizuka, Manami, Wilhelm, Alan, Salomon, Paulin, Reid, Emily E., Lanieri, Leanne, Sikka, Surina, Maloney, Erin K., Harvey, Lauren, Qiu, Qifeng, Archer, Katie E., Bai, Chen, Vitharana, Dilrukshi, Harris, Luke, Singh, Rajeeva, Ponte, Jose F., Yoder, Nicholas C., Kovtun, Yelena, Lai, Katharine C., Ab, Olga, Pinkas, Jan, Keating, Thomas A., Chari, Ravi V.J. · 2018 · Molecular Cancer Therapeutics
Cited by 56

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Tumor-selective delivery of cytotoxic agents in the form of antibody–drug conjugates (ADCs) is now a clinically validated approach for cancer treatment. In an attempt to improve the clinical success rate of ADCs, emphasis has been recently placed on the use of DNA–cross-linking pyrrolobenzodiazepine compounds as the payload. Despite promising early clinical results with this class of ADCs, doses achievable have been low due to systemic toxicity. Here, we describe the development of a new class of potent DNA-interacting agents wherein changing the mechanism of action from a cross-linker to a DNA alkylator improves the tolerability of the ADC. ADCs containing the DNA alkylator displayed similar in vitro potency, but improved bystander killing and in vivo efficacy, compared with those of the cross-linker. Thus, the improved in vivo tolerability and antitumor activity achieved in rodent models with ADCs of the novel DNA alkylator could provide an efficacious, yet safer option for cancer treatment. Mol Cancer Ther; 17(3); 650–60. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-17-0940

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 56

Metadata

Authors
Miller, M. L., Shizuka, M., Wilhelm, A., Salomon, P., Reid, E. E., Lanieri, L., Sikka, S., Maloney, E. K., Harvey, L., Qiu, Q., Archer, K. E., Bai, C., Vitharana, D., Harris, L., Singh, R., Ponte, J. F., Yoder, N. C., Kovtun, Y., Lai, K. C., Ab, O., Pinkas, J., Keating, T. A., & Chari, R. V. J.
Venue
Molecular Cancer Therapeutics
Published
2018-02-28
Volume
17
Issue
3
Pages
650-660
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2790219752
Cited by
56
References
4
FWCI
2.54
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs). https://app.cochat.ai/papers/10.1158/1535-7163.mct-17-0940
The paper
Miller, M. L., Shizuka, M., Wilhelm, A., Salomon, P., Reid, E. E., Lanieri, L., Sikka, S., Maloney, E. K., Harvey, L., Qiu, Q., Archer, K. E., Bai, C., Vitharana, D., Harris, L., Singh, R., Ponte, J. F., Yoder, N. C., Kovtun, Y., Lai, K. C., . . . Chari, R. V. J. (2018). A DNA-Interacting Payload Designed to Eliminate Cross-Linking Improves the Therapeutic Index of Antibody–Drug Conjugates (ADCs). Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-17-0940

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.